We hope that China will join the global market from the beginning of research and development. By the end of 2022, we have achieved the goal of 80% of product research and development and launch in sync with the global market. We also hope that by 2027, all products will be developed and launched in sync with the global market. "Song Faxian, General Manager of Pfizer's Rare Diseases Business Unit in China, stated in an interview with reporters on the 3rd that China's innovation policies and measures to accelerate the review and approval of innovative drugs and devices, Let foreign companies like Pfizer introduce cutting-edge products faster and earlier.
In the interview, the reporter learned that from 2023 to 2025, Pfizer expects to have 17 new products and new indications submitted and approved in China. As of now, 4 models have been approved. The CIIE can help multinational pharmaceutical companies participate in China's innovation and ecology, becoming an important opportunity to smoothly promote product accessibility as soon as possible.
Since its first exhibition at the CIIE, innovative drugs in the field of rare diseases have been one of Pfizer's key showcases. Song Faxian told reporters that in the past few CIIE sessions, Pfizer Rare Disease has improved public awareness of rare diseases and promoted the construction of the rare disease diagnosis and treatment ecosystem through innovative products such as "first exhibition and first show" and a series of targeted projects. Song Faxian told reporters, "The role played by the CIIE in promoting the development of rare diseases is very positive and exciting
For example, in 2019, Pfizer showcased the oral medication for the treatment of rare diseases - chloramphenicol - at the CIIE. In September 2020, chloramphenicol acid was approved in China and listed at the China International Import and Export Fair that year. In 2021, the drug was included in the national medical insurance drug catalog. This year, Pfizer focuses on introducing non factor therapies on the forefront of hemophilia in the field of rare diseases. We hope to take advantage of the opportunity of the CIIE to let more people understand the value of innovative drugs in achieving personalized treatment of hemophilia, thereby promoting drug acceleration and accessibility. We will submit applications simultaneously with the world and become one of the first countries to go public, bringing the latest cutting-edge breakthrough therapies to Chinese patients to meet the unmet needs of disease diagnosis and treatment, "said Song Faxian.
It is revealed that this year, Pfizer has proposed a new concept of "Treat beyond bleeding, Revive free lives" in the field of hemophilia treatment, hoping to shift the treatment goal of hemophilia from "controlling bleeding" to "focusing on hidden bleeding and protecting joint function", and help more hemophilia patients achieve a healthy life.
On the open and communicative platform of the CIIE, Pfizer not only collaborates with the China Rare Disease Alliance to assist in standardized diagnosis and treatment of rare diseases and system construction, but also continuously expands cooperation with patients' organizations, emerging enterprises in the field of big health, and other partners. By means of digitization and other means, the entire chain of disease cognition, diagnosis, treatment, payment, and long-term patient management is demonstrated.
In recent years, China's efforts and achievements in strengthening intellectual property protection and optimizing the business environment have strengthened the confidence of enterprises from around the world in strengthening trade and investment cooperation with China. In May 2023, Pfizer Smart Medical Innovation Center was established in Qiantang District, Hangzhou, aiming to empower the Chinese medical industry with digital innovation, gather top talents in the industry, focus on industry pain points, and solve industry challenges through mobile solutions.
It is revealed that Pfizer China R&D Center plans to achieve global synchronization of key phase III and registration applications for the entire product line within the next five years. This means that by 2027, Pfizer will achieve China's participation in all key phase III clinical trials and include China in the first batch of Pfizer's global new product application regional directory, in order to achieve synchronous submission of the entire product line in China. This will further shorten the time difference between the international and domestic marketing of innovative drugs, allowing domestic patients to receive treatment and survival benefits as soon as possible. (End)